Your browser doesn't support javascript.
loading
Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.
Martins, Mauricio A; Tully, Damien C; Pedreño-Lopez, Núria; von Bredow, Benjamin; Pauthner, Matthias G; Shin, Young C; Yuan, Maoli; Lima, Noemia S; Bean, David J; Gonzalez-Nieto, Lucas; Domingues, Aline; Gutman, Martin J; Maxwell, Helen S; Magnani, Diogo M; Ricciardi, Michael J; Bailey, Varian K; Altman, John D; Burton, Dennis R; Ejima, Keisuke; Allison, David B; Evans, David T; Rakasz, Eva G; Parks, Christopher L; Bonaldo, Myrna C; Capuano, Saverio; Lifson, Jeffrey D; Desrosiers, Ronald C; Allen, Todd M; Watkins, David I.
Afiliação
  • Martins MA; Department of Pathology, University of Miami, Miami, Florida, USA mmartins@med.miami.edu.
  • Tully DC; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Pedreño-Lopez N; Department of Pathology, University of Miami, Miami, Florida, USA.
  • von Bredow B; Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Pauthner MG; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
  • Shin YC; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA.
  • Yuan M; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), The Scripps Research Institute, La Jolla, California, USA.
  • Lima NS; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Bean DJ; International AIDS Vaccine Initiative, AIDS Vaccine Design and Development Laboratory, Brooklyn, New York, USA.
  • Gonzalez-Nieto L; Laboratório de Biologia Molecular de Flavivirus, Instituto Oswaldo Cruz-FIOCRUZ, Rio de Janeiro, Brazil.
  • Domingues A; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Gutman MJ; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Maxwell HS; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Magnani DM; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Ricciardi MJ; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Bailey VK; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Altman JD; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Burton DR; Department of Pathology, University of Miami, Miami, Florida, USA.
  • Ejima K; Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
  • Allison DB; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
  • Evans DT; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.
  • Rakasz EG; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA.
  • Parks CL; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), The Scripps Research Institute, La Jolla, California, USA.
  • Bonaldo MC; School of Public Health, Indiana University Bloomington, Bloomington, Indiana, USA.
  • Capuano S; School of Public Health, Indiana University Bloomington, Bloomington, Indiana, USA.
  • Lifson JD; Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Desrosiers RC; Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, USA.
  • Allen TM; Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, USA.
  • Watkins DI; International AIDS Vaccine Initiative, AIDS Vaccine Design and Development Laboratory, Brooklyn, New York, USA.
J Virol ; 92(16)2018 08 15.
Article em En | MEDLINE | ID: mdl-29875239
ABSTRACT
Certain major histocompatibility complex class I (MHC-I) alleles are associated with spontaneous control of viral replication in human immunodeficiency virus (HIV)-infected people and simian immunodeficiency virus (SIV)-infected rhesus macaques (RMs). These cases of "elite" control of HIV/SIV replication are often immune-mediated, thereby providing a framework for studying anti-lentiviral immunity. In this study, we examined how vaccination impacts SIV replication in RMs expressing the MHC-I allele Mamu-B*17 Approximately 21% of Mamu-B*17+ and 50% of Mamu-B*08+ RMs control chronic-phase viremia after SIVmac239 infection. Because CD8+ T cells targeting Mamu-B*08-restricted SIV epitopes have been implicated in virologic suppression in Mamu-B*08+ RMs, we investigated whether this might also be true for Mamu-B*17+ RMs. Two groups of Mamu-B*17+ RMs were vaccinated with genes encoding Mamu-B*17-restricted epitopes in Vif and Nef. These genes were delivered by themselves (group 1) or together with env (group 2). Group 3 included MHC-I-matched RMs and served as the control group. Surprisingly, the group 1 vaccine regimen had little effect on viral replication compared to group 3, suggesting that unlike Mamu-B*08+ RMs, preexisting SIV-specific CD8+ T cells alone do not facilitate long-term virologic suppression in Mamu-B*17+ RMs. Remarkably, however, 5/8 group 2 vaccinees controlled viremia to <15 viral RNA copies/ml soon after infection. No serological neutralizing activity against SIVmac239 was detected in group 2, although vaccine-elicited gp140-binding antibodies correlated inversely with nadir viral loads. Collectively, these data shed new light on the unique mechanism of elite control in Mamu-B*17+ RMs and implicate vaccine-induced, nonneutralizing anti-Env antibodies in the containment of immunodeficiency virus infection.IMPORTANCE A better understanding of the immune correlates of protection against HIV might facilitate the development of a prophylactic vaccine. Therefore, we investigated simian immunodeficiency virus (SIV) infection outcomes in rhesus macaques expressing the major histocompatibility complex class I allele Mamu-B*17 Approximately 21% of Mamu-B*17+ macaques spontaneously controlled chronic phase viremia after SIV infection, an effect that may involve CD8+ T cells targeting Mamu-B*17-restricted SIV epitopes. We vaccinated Mamu-B*17+ macaques with genes encoding immunodominant epitopes in Vif and Nef alone (group 1) or together with env (group 2). Although neither vaccine regimen prevented SIV infection, 5/8 group 2 vaccinees controlled viremia to below detection limits shortly after infection. This outcome, which was not observed in group 1, was associated with vaccine-induced, nonneutralizing Env-binding antibodies. Together, these findings suggest a limited contribution of Vif- and Nef-specific CD8+ T cells for virologic control in Mamu-B*17+ macaques and implicate anti-Env antibodies in containment of SIV infection.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos de Histocompatibilidade Classe I / Produtos do Gene env / Produtos do Gene nef / Produtos do Gene vif / Síndrome de Imunodeficiência Adquirida dos Símios / Vírus da Imunodeficiência Símia / Vacinas contra a SAIDS Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos de Histocompatibilidade Classe I / Produtos do Gene env / Produtos do Gene nef / Produtos do Gene vif / Síndrome de Imunodeficiência Adquirida dos Símios / Vírus da Imunodeficiência Símia / Vacinas contra a SAIDS Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article